MarketCap
Facebook
X
Telegram
Albireo Pharma Gross Profit | ALBO
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 39.2 M | 8.31 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 39.2 M | 8.31 M | 23.8 M |
Quarterly Gross Profit Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 3.23 M | - | - | - | 2.13 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.23 M | 2.13 M | 2.68 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
160 M | - | - | - |  Russia |
 |
AbbVie
ABBV
|
12.1 B | $ 257.12 | 0.86 % | $ 455 B |  USA |
 |
Ayala Pharmaceuticals
AYLA
|
90 K | - | - | $ 7.46 M |  Israel |
 |
Amryt Pharma plc
AMYT
|
116 M | - | - | $ 621 M |  Britain |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
12 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
1.12 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Advaxis
ADXS
|
90 K | - | -9.65 % | $ 45.9 M | USA |
 |
Abeona Therapeutics
ABEO
|
925 K | $ 5.42 | 0.18 % | $ 287 M | USA |
 |
BioXcel Therapeutics
BTAI
|
24.3 | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
Cyclerion Therapeutics
CYCN
|
2.3 M | $ 23.52 | 458.67 % | $ 98.9 M | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
319 M | $ 2.0 | 0.3 % | $ 726 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-40.6 M | $ 5.12 | 0.1 % | $ 981 M |  Canada |
 |
Ampio Pharmaceuticals
AMPE
|
-523 K | - | -11.43 % | $ 502 K | USA |
 |
NextCure
NXTC
|
22.4 K | $ 7.0 | 0.55 % | $ 19.9 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
1 K | - | 17.91 % | $ 11.1 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
473 M | $ 27.83 | 0.32 % | $ 4.69 B | USA |
 |
SQZ Biotechnologies Company
SQZ
|
21 M | - | 57.95 % | $ 12.8 M | USA |
 |
Berkeley Lights
BLI
|
53.8 M | - | -7.31 % | $ 87 M | USA |
 |
Achieve Life Sciences
ACHV
|
18.2 M | $ 7.06 | 0.41 % | $ 308 M | USA |
 |
Baudax Bio
BXRX
|
-1.24 M | - | 0.59 % | $ 63 K | USA |
 |
Codiak BioSciences
CDAK
|
2.92 K | - | -55.98 % | $ 2.15 M | USA |
 |
ChemoCentryx
CCXI
|
64.9 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
7.32 M | - | - | $ 789 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-2.55 M | - | - | $ 7.29 B | USA |
 |
Aclaris Therapeutics
ACRS
|
172 K | $ 5.32 | 1.27 % | $ 652 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
1.07 | - | - | $ 169 M | USA |
 |
ADMA Biologics
ADMA
|
293 M | $ 9.23 | 0.16 % | $ 2.2 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
62.8 M | $ 24.2 | 0.08 % | $ 3.67 B | USA |
 |
Agenus
AGEN
|
-18.3 M | $ 6.94 | 0.73 % | $ 206 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
117 M | $ 33.6 | 0.16 % | $ 1.95 B | USA |